3-(ethylamino)benzo[e][1,2,4]triazine 1,4-dioxide | 215535-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 3-(ethylamino)benzo[e][1,2,4]triazine 1,4-dioxide
• 英文别名: 1,2,4-Benzotriazin-3-amine, N-ethyl-, 1,4-dioxide；N-ethyl-1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine
• CAS: 215535-58-3
• 化学式: C₉H₁₀N₄O₂
• 分子量: 206.204
• InChiKey: NWSLANWZVFGEIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  75.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  异腈酸2-硝基苯 在 sodium hydroxide 、 氨 、 双氧水 、 溶剂黄146 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 36.5h， 生成 3-(ethylamino)benzo[e][1,2,4]triazine 1,4-dioxide
  参考文献：
  名称：

  某些3-氨基-1,2,4-苯并三嗪-1,4-二氧化物衍生物的合成和低氧细胞毒活性。

  摘要：

  合成了一系列3-氨基-1,2,4-苯并三嗪-1,4-二氧化物衍生物1并评估了其对人白血病细胞系Molt-4，K562，HL60，人肝癌的体外细胞毒活性细胞Hep-G2，缺氧的人前列腺癌细胞PC-3。大多数化合物显示出比TPZ更强的活性。化合物1i和1m对Molt-4和HL-60细胞系显示出令人鼓舞的优异活性。三种潜在的衍生物接受了针对Molt-4和HL-60细胞系的低氧和常氧活性测试，并显示出明显的低氧选择性。进一步的机理研究表明，化合物1i和1k在Molt-4细胞中的细胞毒活性可能是通过调节p53蛋白表达和线粒体膜电位（DeltaPsi（m））来介导的。

  DOI：

  10.1016/j.bmcl.2006.05.095

文献信息

• Synthesis, Structure and Hypoxic Cytotoxicity of 3-Amino-1,2,4-benzotriazine-1,4-dioxide Derivatives
  作者：Faqin Jiang、Qinjie Weng、Rong Sheng、Qing Xia、Qiaojun He、Bo Yang、Yongzhou Hu

  DOI：10.1002/ardp.200600201

  日期：2007.5

  3‐amino‐1,2,4‐benzotriazine‐1,4‐dioxide derivatives were synthesized and screened for their in vitro cytotoxicity against promyelocytic leukemia HL‐60, androgen‐independent prostate tumor PC3, hepatocellular carcinoma Bel‐7402, human esophagus tumor ECA‐109, and human breast tumor MCF‐7 cell lines in hypoxia and in normoxia. Most compounds showed higher cytotoxic activity both in hypoxia and in normoxia

  合成了一系列新型 3-氨基-1,2,4-苯并三嗪-1,4-二氧化物衍生物并筛选了它们对早幼粒细胞白血病HL-60、雄激素非依赖性前列腺肿瘤PC3、肝细胞癌Bel-7402的体外细胞毒性、人食道肿瘤 ECA-109 和人乳腺肿瘤 MCF-7 细胞系在缺氧和常氧条件下。大多数化合物在缺氧和常氧条件下都显示出更高的细胞毒活性。其中，与替拉扎明相比，化合物 61 和 62 显示出更有效的细胞毒活性和低氧选择性。
• Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis
  申请人：Madrid Peter

  公开号：US20130150369A1

  公开（公告）日：2013-06-13

  Benzotriazine doxides are disclosed as drugs targeting mycobacterium tuberculosis , including novel compounds of formula I:

  Benzotriazine doxides被披露为针对结核分枝杆菌的药物，包括公式I的新化合物。
• Discovery and Optimization of Benzotriazine Di-<i>N</i>-Oxides Targeting Replicating and Nonreplicating Mycobacterium tuberculosis
  作者：Sidharth Chopra、Gary A. Koolpe、Arlyn A. Tambo-ong、Karen N. Matsuyama、Kenneth J. Ryan、Tran B. Tran、Rupa S. Doppalapudi、Edward S. Riccio、Lalitha V. Iyer、Carol E. Green、Baojie Wan、Scott G. Franzblau、Peter B. Madrid

  DOI：10.1021/jm300123s

  日期：2012.7.12

  Compounds bactericidal against both replicating and nonreplicating Mtb may shorten the length of TB treatment regimens by eliminating infections more rapidly. Screening of a panel of antimicrobial and anticancer drug classes that are bioreduced into cytotoxic species revealed that 1,2,4-benzotriazine di-N-oxides (BTOs) are potently bactericidal against replicating and nonreplicating Mtb. Medicinal chemistry optimization, guided by semiempirical molecular orbital calculations, identified a new lead compound (20q) from this series with an MIC of 0.31 mu g/mL against H37Rv and a cytotoxicity (CC50) against Vero cells of 25 mu g/mL. 20q also had equivalent potency against a panel of single-drug resistant strains of Mtb and remarkably selective activity for Mtb over a panel of other pathogenic bacterial strains. 20q was also negative in a L5178Y MOLY assay, indicating low potential for genetic toxicity. These data along with measurements of the physiochemical properties and pharmacokinetic profile demonstrate that BTOs have the potential to be developed into a new class of antitubercular drugs.
• BENZOTRIAZINE OXIDES AS DRUGS TARGETING MYCOBACTERIUM TUBERCULOSIS
  申请人：Sri International Inc.

  公开号：EP2800744A1

  公开（公告）日：2014-11-12
• US9663478B2
  申请人：——

  公开号：US9663478B2

  公开（公告）日：2017-05-30